Publications

1. Ciclosporin (Ikervis®) for the treatment of severe keratitis in adult patients with the dry eye syndrome

   The National Health Care Institute has completed its assessment whether ciclosporin (Ikervis®) for the treatment of severe ...

   Report | 18-09-2019

2. Dabrafenib/trametinib (Tafinlar®/Mekinist®) for the adjuvant treatment of adult patients with stage III melanoma

   The National Health Care Institute has completed its assessment of dabrafenib (Tafinlar®) in combination with trametinib ...

   Report | 28-08-2019

3. GVS assessment of fampridine (Fampyra®) for use in a subgroup of MS patients

   The National Health Care Institute has completed its assessment whether fampridine (Fampyra®) can be included in the Medication ...

   Report | 06-08-2019

4. Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) for the treatment of adults infected with HIV-1

   The National Health Care Institute has completed its assessment whether Delstrigo® (doravirine/lamivudine/tenofovir disoproxil ...

   Report | 27-06-2019

5. Doravirine (Pifeltro®) for the treatment of adults infected with HIV-1

   The National Health Care Institute has completed its assessment whether Pifeltro® (doravirine) can be included in the Medication ...

   Report | 27-06-2019

6. Erenumab (Aimovig®) for the prophylaxis of adults with migraine

   The National Health Care Institute has completed its assessment whether erenumab (Aimovig®) for the prophylaxis of adults with ...

   Report | 27-06-2019

7. Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma

   The National Health Care Institute has completed its assessment whether ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line ...

   Report | 29-05-2019

8. Venetoclax (Venclyxto®) in combination with rituximab for the treatment of chronic lymphocytic leukaemia (CLL)

   Zorginstituut Nederland has completed its assessment whether venetoclax (Venclyxto®) in combination with rituximab for the ...

   Report | 08-05-2019

9. Lumacaftor/ivacaftor (Orkambi®) for the treatment of cystic fibrosis

   The National Health Care Institute carried out a marginal assessment in relation to extending the specific conditions for the ...

   Report | 30-04-2019

10. Tezacaftor/ivacaftor (Symkevi®) with ivacaftor monopreparation (Kalydeco®) for the treatment of cystic fibrosis

    The National Health Care Institute carried out an assessment in relation to extending the specific conditions for the medicinal ...

    Report | 24-04-2019